Benda Pharmaceutical (APSP) Inactive 10-Q2009 Q1 Quarterly report

Filed: 20 May 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: added, agency, alleging, Article, building, bureau, ceased, charge, collateral, complaint, component, confirmed, content, contract, CPLR, default, deficit, delinquent, directly, distributed, distribution, DNAVEC, embedded, equivalent, ere, Excalibur, exclusive, factor, fairly, favor, FIN, foreclosed, fourth, freestanding, frozen, fulfill, global, hereof, hierarchy, identical, Indexed, indirectly, insignificant, inspection, Instrument, insufficient, intent, Interpretation, Japanese, jurisdiction, launch, lender, leverage, License, LP, main, medium, meet, mended, methodology, modifying, motion, observable, offering, official, orderly, packing, Partnership, platform, pledged, Pope, prior, profile, prospective, prospectively, proven, quoted, random, reclaimed, reclassification, recognition, recover, recovery, redsuction, Regulation, repaid, repay, restructuring, reversed, revised, seasonal, separately, Shuhai, size, strictly, sued, sum, Supreme, SX, thereon, thereto, thsssssserefore, trademarked, trail, trial, unadjusted, uncertain, Uncertainty, unobservable, valid, vary, VAT, worth, York

Removed: acquirer, acquiring, Amendment, authorized, base, behalf, Board, compensation, CONDENSED, deconsolidation, discharge, disclosing, dropped, duly, element, employee, existing, expand, FDA, footnote, grant, increment, noncontrolling, objective, parent, promotional, registrant, shown, single, standard, turned, undersigned

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

APSP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with this Quarterly Report of Benda Pharmaceutical, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yiqing Wan, President, Chief Executive Officer and Director of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

Such Quarterly Report on Form 10-Q for the period ending March 31, 2009, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in such Quarterly Report on Form 10-Q for the period ending March 31, 2009, fairly presents, in all material respects, the financial condition and results of operations of Benda Pharmaceutical, Inc.

Date: May 19, 2009

/s/ Yiqing Wan

Yiqing Wan

President, CEO and

Director

Exhibit 32.1

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with this Quarterly Report of Benda Pharmaceutical, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Eric Yu, Chief Financial Officer and Principal Accounting Officer and Director of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

Such Quarterly Report on Form 10-Q for the period ending March 31, 2009, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

Date: May 19, 2009

/s/ Eric Yu

Eric Yu

CFO and Principal

Accounting Officer and

Director

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.